Advanced coronary artery disease: Appropriate end points for trials of novel therapies
Authors:
- David E. KandzariDKDavid E. Kandzari
- La Choi LamLLLa Choi Lam
- Eric L. EisensteinEEEric L. Eisenstein
- Nancy Clapp-ChanningNCNancy Clapp-Channing
- Jennifer T. FineJFJennifer T. Fine
- Robert M. CaliffRCRobert M. Califf
- Daniel B. MarkDMDaniel B. Mark
- James G. JollisJJJames G. Jollis
- 1 November 2001
- journal article
- Published by Elsevier in American Heart Journal
- Vol. 142 (5) , 843-851
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000JACC, 2000
- Transmyocardial revascularization with CO2 laser in patients with refractory angina pectorisJACC, 2000
- Comparison of Transmyocardial Revascularization with Medical Therapy in Patients with Refractory AnginaNew England Journal of Medicine, 1999
- Transmyocardial Revascularization with a Carbon Dioxide Laser in Patients with End-Stage Coronary Artery DiseaseNew England Journal of Medicine, 1999
- Economic Assessment of Low-Molecular-Weight Heparin (Enoxaparin) Versus Unfractionated Heparin in Acute Coronary Syndrome PatientsCirculation, 1998
- Multimorbidity in General Practice: Prevalence, Incidence, and Determinants of Co-Occurring Chronic and Recurrent DiseasesJournal of Clinical Epidemiology, 1998
- The MOS 36-ltem Short-Form Health Survey (SF-36): III. Tests of Data Quality, Scaling Assumptions, and Reliability Across Diverse Patient GroupsMedical Care, 1994
- A brief self-administered questionnaire to determine functional capacity (The Duke Activity Status Index)The American Journal of Cardiology, 1989
- Twelve-Year Follow-up of Survival in the Randomized European Coronary Surgery StudyNew England Journal of Medicine, 1988
- A Randomized Trial of Coronary Artery Bypass SurgeryNew England Journal of Medicine, 1985